Treatment with SGLT2 inhibitors resulted in a lower risk of worsening heart failure (defined as hospitalisation or unexpected visit for heart failure) or cardiovascular death than placebo in the two trials [13, 14]. The gene discussed is SLC5A2; the disease is heart failure.